|
Phase II trial of gemcitabine and nab-paclitaxel for recurrent osteosarcoma: A report from the National Pediatric Cancer Foundation. |
|
|
Consulting or Advisory Role - Y-mAbs Therapeutics |
|
|
Consulting or Advisory Role - Amgen; Bayer (Inst) |
Research Funding - Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); E.R. Squibb Sons, LLC (Inst); Incyte (Inst); Jazz Pharmaceuticals (Inst); Lilly (Inst); Merck (Inst); Pfizer (Inst); Salarius Pharmaceuticals (Inst); Turning Point Therapeutics (Inst) |
(OPTIONAL) Uncompensated Relationships - Children's Oncology Group Foundation; The Pablove Foundation |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Novartis |
|
|
Consulting or Advisory Role - Day One Therapeutics |
Research Funding - Kura Oncology; Novartis Institutes for BioMedical Research |
Patents, Royalties, Other Intellectual Property - U.S. Provisional App. No. 63184422; Compounds and Compositions for the Treatment of Malignant Peripheral Nerve Sheath Tumor (MPNST) Inventors: Novartis Institute for Biomedical Research, Pratilas, CA, Wang J. (Inst); US20080131885A1 U.S. Patent. Biomarkers for cancer treatment. (Inst) |
|
|
Consulting or Advisory Role - Fennec Pharma; Foundation Medicine; Ipsen |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Eisai; Pfizer; SpringWorks Therapeutics |
|
|
Consulting or Advisory Role - Ymabs Therapeutics Inc |
Speakers' Bureau - SERVIER |